Skip to main content

Press Releases and Ad-hoc Announcements

13 October 2016
PR: WILEX AG: Interim Management Statement on the First Nine Months of 2016
PDF
11 October 2016
AH: WILEX AG secures further financing with shareholder loan based on an existing financing commitment
PDF
27 September 2016
PR: WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production
PDF
19 September 2016
PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center
PDF
14 July 2016
PR: WILEX publishes Half-yearly Financial Report
PDF
28 June 2016
PR: WILEX AG: European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin
PDF
14 June 2016
PM: Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pahrma collaborate to create improve cancer therapeutics
PDF
02 June 2016
AH: WILEX AG announces change on the Executive Management Board
PDF
02 June 2016
PR: WILEX AG announces change on the Executive Management Board
PDF
25 April 2016
PR: WILEX AG successfully completes capital increase
PDF
14 April 2016
PR: WILEX AG: Interim management statement on the first quarter of 2016
PDF
06 April 2016
PR: WILEX AG plans change on Supervisory Board
PDF
22 March 2016
PR: WILEX announces financial figures for the 2015 financial year and reports on course of business
PDF
02 February 2016
PR: WILEX AG: US-patent office granted patent for amatoxin conjugates for tumour therapy
PDF
13 January 2016
PR: WILEX’s partner Link Health submits IND application for clinical Phase I with the uPA inhibitor MESUPRON® in China
PDF